Medinox Appoints F. David King as Vice President of Corporate Development

San Diego, California (March 18, 2002) Medinox, Inc. is pleased to announce today that F. David King has joined its executive team as Vice President of Corporate Development. In this position, Mr. King's primary responsibility will be to establish collaborative partnerships for Medinox's clinical drug development programs. Mr. King reports to Monte Lai, Ph.D., Medinox's President & CEO.

Mr. King has over 21 years of experience in business development and licensing as a pharmaceutical industry executive. His expertise in this area has led to the completion of significant corporate development deals with industry partners.

Mr. King comes to Medinox from Harrington Pharmaceuticals Inc, a San Diego-based pharmaceutical company, at which he was co-founder and acting CEO. Prior to Harrington Pharmaceuticals, Mr. King was Senior Director, Business Development for Maxim Pharmaceuticals, Inc.

Previously, Mr. King held several executive and management level positions at various pharmaceutical companies, including DepoTech Corporation (now SkyePharma Ltd.), and Glaxo Inc. (now GlaxoSmithKline). He began his pharmaceutical industry career in sales and marketing for Stuart Pharmaceuticals (now AstraZeneca). Mr. King holds a bachelor's degree in Business Administration from Goshen College in Goshen, IN.

"Medinox is moving into the clinic with four Phase I/IIa trials," noted David King. "Their novel products have tremendous potential to address unmet medical needs in therapeutic categories having substantial revenue potential. This is an exciting time to join Medinox."

Dr. Monte Lai commented, "Medinox is very fortunate to add such an experienced professional to our management team. He will play a critical role in partnering our clinical drug development programs, which will be key to the future growth and success of the company."

About Medinox, Inc. Medinox is the leader in NO-blocking therapeutics and is developing a broad technology platform to treat a wide variety of unmet medical needs including, sepsis, diabetes, acute respiratory distress syndrome (ARDS), and arthritis. In addition to its NO blocker technology, Medinox is also developing new and safer NSAIDs and new therapeutics for sickle cell anemia.

For information on Medinox, please visit the company's website at www.medinox.com.